Sugi Predict

Sugi Predict / Compounds / SCHEMBL52267

SCHEMBL52267

SCHEMBL52267

COC(=O)C1CCC(OC)(OC)C1

nearest known ligand 0.38

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.38
▸ CHRNB2 P17787 2/20 0.37
▸ CHRNA4 P43681 2/20 0.37
▸ CHRNB4 P30926 1/20 0.37
▸ CHRNA3 P32297 1/20 0.37
▸ CHRNA7 P36544 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ BRD4 O60885 1/20 0.34
▸ GAA P10253 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ HIF1A Q16665 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26929285 1.00 TP53 (0.38) TP53CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL29362369 1.00 TP53 (0.38) TP53CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL28016776 0.88 TP53 (0.44) TP53CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL449125 0.83 CHRNB2 (0.42) TP53CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL3165024 0.82 HRH3 (0.37) —
SCHEMBL25604017 0.82 CYP3A4 (0.42) GAAALDH1A1
SCHEMBL28635475 0.82 GRM2 (0.47) CYP1A2ALDH1A1
SCHEMBL28735172 0.81 CHRNB2 (0.35) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7
SCHEMBL27596749 0.78 TP53 (0.39) TP53CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL17212631 0.78 APLNR (0.41) TP53CHRNB2CHRNA4CHRNB4CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250114461-A1 CDK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-04-10 — — US disclosed
US-12097261-B2 CDK2 degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-09-24 — — US disclosed
CN-117715904-A CDK2 degrading agents and uses thereof 凯麦拉医疗公司 2024-03-15 — — CN disclosed
EP-4334307-A1 CDK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-03-13 — — EP disclosed
WO-2023239629-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE CDK2 Plexium, Inc. (US) 2023-12-14 — — WO disclosed
WO-2023239629-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE CDK2 Plexium, Inc. (US) 2023-12-14 — — WO disclosed
US-20230321042-A1 COMBINATION THERAPY PFIZER INC. (US) 2023-10-12 — — US disclosed
US-20230321042-A1 COMBINATION THERAPY PFIZER INC. (US) 2023-10-12 — — US disclosed
US-20230321042-A1 COMBINATION THERAPY PFIZER INC. (US) 2023-10-12 — — US disclosed
US-11773082-B2 CDK2 inhibitors PFIZER INC. (US) 2023-10-03 — — US disclosed
US-20070117797-A1 Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity MERCK SHARP & DOHME CORP. 2007-05-24 — — US disclosed
US-20070117797-A1 Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity MERCK SHARP & DOHME CORP. 2007-05-24 — — US disclosed
US-7166614-B2 Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity MERCK & CO., INC. (US) 2007-01-23 — — US disclosed
US-7166614-B2 Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity MERCK & CO., INC. (US) 2007-01-23 — — US disclosed
EP-1318811-B1 CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO INC (US) 2006-08-30 — — EP disclosed
EP-1318811-A4 CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO INC (US) 2004-07-14 — — EP disclosed
EP-1318811-A1 CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Merck & Co., Inc. (US) 2003-06-18 — — EP disclosed
US-6545023-B2 For treating rheumatoid arthritis; for examle, 1-(4-(4-fluorophenyl)piperidin-1-yl),3-(2-methoxy-4 -chlorobenzylaminocarbonyl),3-isopropyl-cyclopentane MERCK & CO., INC. 2003-04-08 — — US disclosed
US-20020049222-A1 Cyclopentyl modulators of chemokine receptor activity MERCK SHARP & DOHME CORP. 2002-04-25 — — US disclosed
WO-2002013824-A1 CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO., INC. (US) 2002-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117797-A1 Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity CCR7, ACKR3, CCR2 TP53 4409/4885CHRNB2 3165/4885CHRNA4 2931/4885
US-20020049222-A1 Cyclopentyl modulators of chemokine receptor activity CCR1, CCRL2, CCR5 TP53 4835/4885CHRNB2 895/4885CHRNA4 554/4885
US-11773082-B2 CDK2 inhibitors CDK2, CDK1, CCNI TP53 82/4885CHRNB2 4782/4885CHRNA4 4812/4885
US-12097261-B2 CDK2 degraders and uses thereof CDK2, CDK20, CDK1 TP53 76/4885CHRNB2 4374/4885CHRNA4 4492/4885
US-20250114461-A1 CDK2 DEGRADERS AND USES THEREOF CDK2, CDK20, CDK1 TP53 76/4885CHRNB2 4374/4885CHRNA4 4492/4885
US-20230321042-A1 COMBINATION THERAPY CDK4, CDK6, CDK2 TP53 136/4885CHRNB2 4871/4885CHRNA4 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.